RxDoctor Payments Data

Lee Kubersky, MD

Neurology · Meadowbrook, PANPI 1508071952

Payments from drug & device makers

$59,191in general payments, 2019–2025

Across 642 payments — averaging $92.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$40K
  • UCB, Inc.$4K
  • MDD US Operations, LLC$4K
  • Boston Scientific$1K
  • Abbott$1K
  • Biogen$1K
  • plus $8K from 53 others

What the payments were for

  • Consulting fees$3,6906%
  • Speaking & faculty fees$41,80071%
  • Travel & lodging$8861%
  • Food & beverage$12,65121%
  • Education$1630%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)134$40,281
UCB, Inc.66$4,032
MDD US Operations, LLC24$3,790
Boston Scientific13$1,421
Abbott9$1,031
Biogen29$1,019
Sanofi18$580
EMD Serono, Inc.23$468
Teva Pharmaceuticals USA, Inc.27$458
Amneal Pharmaceuticals LLC25$455
Acadia Pharmaceuticals Inc36$422
Acorda Therapeutics, Inc18$386
Pfizer20$321
Novartis15$298
Medtronic(2 entities)9$296
Harmony Biosciences LLC8$289
SK Life Science, Inc.9$269
Kyowa Kirin, Inc.10$251
AstraZeneca(2 entities)9$220
Neurocrine Biosciences, Inc.10$213
Lilly USA, LLC11$205
Supernus Pharmaceuticals, Inc.12$174
Lundbeck LLC9$158
Jazz Pharmaceuticals Inc.7$158
E.r. Squibb & Sons, L.L.C.2$146
Adamas Pharmaceuticals, Inc.7$141
Johnson & Johnson6$139
Sunovion Pharmaceuticals Inc.7$109
Bristol Myers Squibb5$97
Ipsen Biopharmaceuticals, Inc5$97
Biohaven Pharmaceutical Holding Company Ltd.4$89
Avanir Pharmaceuticals, Inc.4$86
Eisai Inc.3$80
Arbor Pharmaceuticals, Inc.4$80
GE HealthCare4$79
Insightec,inc1$74
Genentech USA, Inc.3$73
Amgen4$72
Merz Pharmaceuticals, LLC3$70
Upsher-smith Laboratories LLC3$63
Vertical Pharmaceuticals, LLC3$46
Avion Pharmaceuticals2$44
Assertio Therapeutics, Inc.3$42
Biohaven Pharmaceuticals, Inc.2$41
Revance Therapeutics, Inc.2$38
Argenx US, Inc.1$32
Axsome Therapeutics, Inc.1$30
TG Therapeutics, Inc.1$24
Catalyst Pharmaceuticals, Inc.1$23
CSL Behring1$23
Banner Life Sciences, LLC1$21
Fujirebio Diagnostics, Incorporated1$21
Otsuka America Pharmaceutical, Inc.1$21
Merz North America, Inc.1$17
GRT US Holding, Inc.1$17
Azurity Pharmaceuticals, Inc.1$17
Corium, LLC1$16
Sumitomo Pharma America, Inc.1$16
Life Molecular Imaging Ltd1$8

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$59,191 in reported general payments places this provider in the 80th percentile of 941 neurology providers in Pennsylvania.

See all neurology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$210,673
Medicare patients
538
Services billed
12,547

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate59$348,745
ApokynApomorphine Hcl12$278,503
CopaxoneGlatiramer Acetate47$272,648
GocovriAmantadine Hcl59$218,425
RytaryCarbidopa/Levodopa41$78,321
NourianzIstradefylline39$77,680
IngrezzaValbenazine Tosylate14$77,177
Teriflunomide12$30,180
Carbidopa-LevodopaCarbidopa/Levodopa712$27,622
Rasagiline Mesylate127$25,259
NeuproRotigotine17$23,013
Dimethyl Fumarate14$18,486
Emgality PenGalcanezumab-Gnlm13$15,677
XcopriCenobamate12$14,272
Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone39$14,056

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$422$348,74559 claims
Teva Pharmaceuticals USA, Inc.Copaxone$458$272,64847 claims
MDD US Operations, LLCGocovri$3,790$218,42559 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide, Mycophenolate Mofetil$455$82,03677 claims
Kyowa Kirin, Inc.Nourianz$251$77,68039 claims
Neurocrine Biosciences, Inc.Ingrezza$213$77,17714 claims
UCB, Inc.Neupro$4,032$23,01317 claims
SK Life Science, Inc.Xcopri$269$14,27212 claims
Upsher-smith Laboratories LLCTopiramate$63$1,92699 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 941 neurology providers in Pennsylvania.

Other neurology in Meadowbrook

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →